The Venture Codex

Led · Series B · May 2026

NUCLIDIUM focuses on copper isotopes for radiotheranostics, using copper-61 for imaging and copper-67 for therapeutic applications. Its lead programs are NU101 for metastatic castration-resistant prostate cancer and NU201 for metastatic breast cancer, both slated to begin therapeutic phase 1/2a trials this year. The company reports that diagnostic phase 1/2 trial data to date show strong momentum, according to CEO and co-founder Leila Jaafar. NUCLIDIUM operates sites in Basel and Munich and is currently in the clinical development phase. It plans to expand its international production and manufacturing network for diagnostics and therapy and to develop new target structures in preclinical work to address additional solid tumor types.

Participated · Seed · Apr 2026

Tacalyx focuses on discovery and development of antibodies against tumour associated carbohydrate antigens (TACAs) for cancer treatment. The company is developing modalities including antibody drug conjugates (ADCs) and other antibody-based therapies using a proprietary technology platform to exploit TACAs as targets. Its lead disclosed programme is TCX-201, an ADC directed at an undisclosed TACA, which the company plans to advance through preclinical development with proceeds from its recent financing. Tacalyx is expanding a differentiated pipeline of programmes built on its platform. The company is led by CEO Jean Engela and is headquartered in Berlin, Germany.

Led · Seed · Mar 2026

Laigo Bio is developing the SureTACs platform to generate bispecific antibodies that selectively degrade disease-causing membrane proteins by pairing an E3 ligase with a target protein to trigger ubiquitination and lysosomal degradation. The approach is intended to enable highly selective elimination of disease-driving membrane targets and to produce first-in-class, dual-targeted therapies. Laigo is focusing its programs on oncology as well as autoimmune and immunology indications, including graft rejection, and is advancing multiple candidate programs. The company reports in vivo and in vitro efficacy with a claimed high degree of selectivity and improved toxicity and safety. Laigo is advancing its oncology pipeline toward clinical development and progressing three autoimmune/immunology programs with support from its recent seed financing.

Participated · Series A · Mar 2026

Alveus Therapeutics is advancing a pipeline of peptide-based treatments aimed at delivering durable weight loss and improved metabolic control. Its lead candidate, ALV-100, is a bifunctional molecule that combines glucose-dependent insulinotropic polypeptide receptor antagonism with glucagon-like peptide-1 receptor agonism, and is positioned to enter Phase 3 after characterization work funded by the new capital. A second program, ALV-200, is a highly selective amylin receptor 3 agonist, while the company is also progressing an oral amylin program expected to begin first-in-human studies within 18 months. Alveus focuses on therapies with sustained efficacy, improved tolerability, and reduced treatment burden compared with existing obesity drugs. The firm plans to run multiple development programs in parallel over the next 18–24 months to reach key value inflection points, including advancing ALV-100 to a Phase 3-ready state and moving early-stage assets into the clinic. Its recent $197 million Series A financing provides the capital to execute these objectives and expand its investor base.

Participated · Series B · Nov 2025

Founded in 2014, Damae Medical’s mission is to let dermatologists observe skin at the cellular scale directly during consultations. Its core product, deepLive™, delivers instant, non-invasive cellular imaging supported by a real-time, CE-certified AI engine. Backed by more than a decade of R&D and over 250 scientific publications, deepLive™ is already installed in 120+ sites across 15+ countries, spanning hospitals and private practices. The system is used from initial diagnosis to intra-operative surgical guidance, helping thousands of patients avoid unnecessary biopsies, repeat surgeries and long waiting times. With the technology now commercially launched, the company plans to broaden access beyond early pioneer centers and make digital biopsy a routine part of dermatological care. The newly secured Series B funding strengthens its financial position and fuels this expansion. Damae Medical continues to focus on accelerating adoption, improving accuracy and reducing invasiveness in skin-cancer management.